ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Cryopreservative Bioink Enables Direct Bioprinting of Adherent Cells.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innovative 3D-bioprinted microfibers in calcium phosphate cement platform with Nell-1 to activate nerve-bone axis for synergistic bone, vasculature, and nanofibrous nerve regeneration.Smart molecules : open access · 2026Article
- Meniscus Tissue Engineering Scaffolds: Biomaterials, Biofabrication, and Translation.Polymers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Cryopreservation-integrated bioprinting represents a promising approach for tissue regeneration by combining cell-laden bioink freezing with direct post-thaw printing, bypassing traditional culturing steps. However, key challenges remain: ice crystallization compromises cellular viability, while hydrogel structural integrity deteriorates, impairing printability. We present a biphasic bioink platform for cryopreservation-enabled three-dimensional (3D) bioprinting-CAMP (Cryopreservation for Adhesion and Maintenance Printing), which enables direct 3D printing at 4-8°C post liquid nitrogen storage (-196°C). CAMP inhibits ice recrystallization through hydrogen bond-mediated water immobilization, achieving approximately 80% cell viability without the use of toxic cryoprotectants. Cryopreserved cells in the bioink retained focal adhesions and increased phosphorylated FAK expression, and the bioink exhibited approximately ten fold higher ice recrystallization inhibition than phosphate-buffered saline. Mechanistically, CAMP suppressed cell death via phospho-FAK signaling. In vivo evaluation using a rat femoral defect model demonstrated the therapeutic efficacy of CAMP, with cryopreserved constructs promoting complete bone regeneration within three months. CAMP overcomes the key limitations of conventional biofabrication by combining cell cryopreservation, bioprinting, and functional tissue formation into a single workflow. By bridging cryopreservation and bioprinting, CAMP represents a significant advance toward clinically viable, ready-to-implant engineered tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.